WO2020076738A3 - Composés à liaison protéinique - Google Patents

Composés à liaison protéinique Download PDF

Info

Publication number
WO2020076738A3
WO2020076738A3 PCT/US2019/055067 US2019055067W WO2020076738A3 WO 2020076738 A3 WO2020076738 A3 WO 2020076738A3 US 2019055067 W US2019055067 W US 2019055067W WO 2020076738 A3 WO2020076738 A3 WO 2020076738A3
Authority
WO
WIPO (PCT)
Prior art keywords
bind
rapamycin
compounds
proteins
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/055067
Other languages
English (en)
Other versions
WO2020076738A2 (fr
Inventor
Joseph Henri Bayle
Slawomir Szymanski
Matthew Robert Collinson-Pautz
Steven Mark TOLER
David Michael Spencer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellicum Pharmaceuticals Inc
Original Assignee
Bellicum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellicum Pharmaceuticals Inc filed Critical Bellicum Pharmaceuticals Inc
Publication of WO2020076738A2 publication Critical patent/WO2020076738A2/fr
Publication of WO2020076738A3 publication Critical patent/WO2020076738A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La technologie concerne en partie des composés qui se lient à des protéines. Dans certains exemples, les composés peuvent se lier à des protéines de liaison à la rapamycine. Dans certains exemples, les composés peuvent se lier à des protéines cellulaires et/ou des formes de variants de protéines cellulaires de liaison à la rapamycine et/ou à des analogues de la rapamycine. Dans certains exemples, les composés se lient à des protéines multimériques de liaison à la rapamycine et/ou à des analogues de la rapamycine, par exemple une protéine FKBP12 (et/ou des variants de celle-ci) et un polypeptide mTOR et/ou un domaine tel que FRB, et/ou des variants de celui-ci. L'invention concerne des composés comprenant ceux ayant une structure de formule A, dans laquelle les fractions R20, R21 et R22 sont décrites ici.
PCT/US2019/055067 2018-10-12 2019-10-07 Composés à liaison protéinique Ceased WO2020076738A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744813P 2018-10-12 2018-10-12
US62/744,813 2018-10-12

Publications (2)

Publication Number Publication Date
WO2020076738A2 WO2020076738A2 (fr) 2020-04-16
WO2020076738A3 true WO2020076738A3 (fr) 2020-05-22

Family

ID=70165276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/055067 Ceased WO2020076738A2 (fr) 2018-10-12 2019-10-07 Composés à liaison protéinique

Country Status (1)

Country Link
WO (1) WO2020076738A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
EP4272825A3 (fr) 2019-01-22 2023-12-06 Aeovian Pharmaceuticals, Inc. Modulateurs de mtorc et leurs utilisations
BR112022010754A2 (pt) * 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
MX2022011964A (es) 2020-03-27 2022-12-02 Aeovian Pharmaceuticals Inc Moduladores de mtorc1 y usos de los mismos.
CN116322677B (zh) * 2020-07-21 2025-09-23 艾奥维安制药公司 Mtorc1调节剂及其用途
CN114539288B (zh) * 2020-11-24 2024-01-30 鲁南制药集团股份有限公司 一种依维莫司的制备方法
JP2024503898A (ja) * 2021-01-22 2024-01-29 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体及びその使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170831A1 (en) * 1984-12-03 2003-09-11 Fujisawa Pharmaceutical Co. Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US20090239855A1 (en) * 2004-12-20 2009-09-24 Wyeth Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological, Proliferative, and Inflammatory Disorders
US20090253732A1 (en) * 2004-08-11 2009-10-08 Biotica Technology Limited Production Of Polyketides And Other Natural Products
US20160176893A1 (en) * 2013-07-09 2016-06-23 Isomerase Therapeutics Limited Rapamycin analogues and their pharmaceutical use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170831A1 (en) * 1984-12-03 2003-09-11 Fujisawa Pharmaceutical Co. Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US20090253732A1 (en) * 2004-08-11 2009-10-08 Biotica Technology Limited Production Of Polyketides And Other Natural Products
US20090239855A1 (en) * 2004-12-20 2009-09-24 Wyeth Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological, Proliferative, and Inflammatory Disorders
US20160176893A1 (en) * 2013-07-09 2016-06-23 Isomerase Therapeutics Limited Rapamycin analogues and their pharmaceutical use

Also Published As

Publication number Publication date
WO2020076738A2 (fr) 2020-04-16

Similar Documents

Publication Publication Date Title
EP4382167A3 (fr) Composés comprenant un lieur pour augmenter la stabilité du transcyclooctène
EP4524237A3 (fr) Compositions de protéines anti-vegf et leurs procédés de production
WO2020068752A8 (fr) PROTÉINES DE LIAISON SIRPα ET MÉTHODES D'UTILISATION DE CELLES-CI
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
EP4559323A3 (fr) Sources de protéines d'origine non animale présentant des propriétés fonctionnelles
EP4242304A3 (fr) Procédés et réactifs pour l'analyse d'interfaces protéine-protéine
BR112013008407A2 (pt) antígenos de clostridium difficile
UA103602C2 (ru) АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА
WO2020242988A3 (fr) Agents d'affinité
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
WO2018050902A3 (fr) Multimères, tétramères et octamères
MX2025014195A (es) Metodos y reactivos para analizar las interfaces entre proteinas
WO2015006337A3 (fr) Compositions et procédés permettant d'augmenter la demi-vie d'une protéine dans un sérum
EP3543335A3 (fr) Protéines de fusion d'intéine solubles et procédés de purification de biomolécules
AU2017269839A1 (en) Methods for treatment of refractory generalized myasthenia gravis
EP2203468B8 (fr) Nouveaux peptides antiviraux qui empêchent la liaison du virus à dlc8
BR112022003357A2 (pt) Compostos heterocíclicos
EP4306544A3 (fr) Production de proteines heteromultimeriques au moyen de cellules mammiferes
BR112014024751A2 (pt) antígenos de clostridium difficile
PH12022550698A1 (en) Treatment of alcoholic hepatitis
EP4257193A3 (fr) Protéines de liaison trispécifiques et/ou trivalentes
WO2020115083A3 (fr) Amphipols
PE20200487A1 (es) Proteinas de union al antigeno anti-jagged1
WO2020176871A8 (fr) Anticorps contre la maladie de kawasaki identifiant des peptides d'hépacivirus
PH12021553121A1 (en) Novel cthrc1-specific antibody and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19872073

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19872073

Country of ref document: EP

Kind code of ref document: A2